These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 12717213

  • 1. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
    Stratta RJ, Alloway RR, Lo A, Hodge E.
    Transplantation; 2003 Apr 27; 75(8):1260-6. PubMed ID: 12717213
    [Abstract] [Full Text] [Related]

  • 2. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab.
    Stratta RJ, Alloway RR, Lo A, Hodge EE, PIVOT Study Group.
    Transplant Proc; 2004 May 27; 36(4):1080-1. PubMed ID: 15194375
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Clin Transplant; 2002 Feb 27; 16(1):60-8. PubMed ID: 11982617
    [Abstract] [Full Text] [Related]

  • 4. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years.
    Stratta RJ, Alloway RR, Lo A, Hodge EE.
    Transplant Proc; 2005 Oct 27; 37(8):3531-4. PubMed ID: 16298651
    [Abstract] [Full Text] [Related]

  • 5. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan 27; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

  • 6. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience.
    Ji SM, Li LS, Cheng Z, Cheng DR, Sun QQ, Chen JS, Sha GZ, Liu ZH.
    Transplant Proc; 2007 Jun 27; 39(5):1396-401. PubMed ID: 17580147
    [Abstract] [Full Text] [Related]

  • 7. Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Stratta RJ, Alloway RR, Lo A, Hodge EE.
    Transplant Proc; 2005 Oct 27; 37(8):3527-30. PubMed ID: 16298650
    [Abstract] [Full Text] [Related]

  • 8. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
    Dresske B, Zavazava N, Jenisch S, Exner B, Lenz P, El Mokhtari NE, Kremer B, Faendrich F.
    Transplantation; 2003 Apr 27; 75(8):1286-91. PubMed ID: 12717217
    [Abstract] [Full Text] [Related]

  • 9. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Hodge EE, PIVOT Study Group.
    Transplant Proc; 2005 Mar 27; 37(2):1289-90. PubMed ID: 15848699
    [Abstract] [Full Text] [Related]

  • 10. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO.
    Transpl Int; 2001 Dec 27; 14(6):396-404. PubMed ID: 11793037
    [Abstract] [Full Text] [Related]

  • 11. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.
    Nephrology (Carlton); 2008 Jun 27; 13(3):251-5. PubMed ID: 18221256
    [Abstract] [Full Text] [Related]

  • 12. Rejection after simultaneous pancreas-kidney transplantation.
    Arbogast H, Malaise J, Illner WD, Tarabichi A, Dieterle C, Landgraf R, Land W, Euro-SPK Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20 Suppl 2():ii11-7, ii62. PubMed ID: 15814544
    [Abstract] [Full Text] [Related]

  • 13. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS, Sollinger HW, Humar A, Sutherland DE, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ.
    Transplantation; 2001 Nov 27; 72(10):1637-43. PubMed ID: 11726823
    [Abstract] [Full Text] [Related]

  • 14. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
    Stratta RJ, Alloway RR, Lo A, Hodge EE, PIVOT Study Group.
    Transplant Proc; 2004 May 27; 36(4):1082-3. PubMed ID: 15194376
    [Abstract] [Full Text] [Related]

  • 15. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 16. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids.
    Kobashigawa J, David K, Morris J, Chu AH, Steffen BJ, Gotz VP, Gordon RD.
    Transplant Proc; 2005 Mar 27; 37(2):1333-9. PubMed ID: 15848713
    [Abstract] [Full Text] [Related]

  • 17. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
    Ailawadi G, Smith PW, Oka T, Wang H, Kozower BD, Daniel TM, Kron IL, Jones DR.
    J Thorac Cardiovasc Surg; 2008 Mar 27; 135(3):594-602. PubMed ID: 18329476
    [Abstract] [Full Text] [Related]

  • 18. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Morris JA, Hanson JE, Steffen BJ, Chu AH, Chi-Burris KS, Gotz VP, Gordon RD.
    Clin Transplant; 2005 Jun 27; 19(3):340-5. PubMed ID: 15877795
    [Abstract] [Full Text] [Related]

  • 19. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S, Gondolesi G, Polat K, Ben-Haim M, Artis T, Fishbein TM, Sheiner PA, Kim-Schluger L, Schwartz ME, Miller CM.
    Liver Transpl; 2001 Mar 27; 7(3):220-5. PubMed ID: 11244163
    [Abstract] [Full Text] [Related]

  • 20. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A, Perez-Villa F, Vallejos I, Roig E.
    Transplant Proc; 2005 Nov 27; 37(9):4036-8. PubMed ID: 16386620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.